Terra Furney, PharmD, MHAa,b,c; Amy Horowitz, PharmDa,b,c; John Malamakal, PharmD, MSa,b,c; Christopher R. Frei, PharmDa,b,c
Correspondence: Terra Furney (terrafurney@gmail.com)
aSouth Texas Veterans Health Care System, San Antonio
bCollege of Pharmacy, University of Texas at Austin, San Antonio
cJoe R. & Teresa Long School of Medicine, UT Health, San Antonio
Author disclosures
In the previous 3 years, AstraZeneca provided funding to South Texas Veterans Health Care System; College of Pharmacy, University of Texas at Austin; and the Joe R. & Teresa Long School of Medicine, UT Health for Christopher Frei for research. The remaining authors report no actual or potential conflicts of interest or outside sources of funding with regard to this article.
Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.
Ethics and consent
This study was deemed by the local institutional review board (The University of Texas Health Science Center at San Antonio) to be exempt from review before the initiation of data collection; it was deemed nonregulated research as this was a quality improvement project.
Based on the incidence of primary and secondary outcomes associated with using daily filgrastim injections as primary prophylaxis in this study, additional measures such as tracking postnadir ANCs should be performed to ensure patients receive an appropriate number of filgrastim doses to prevent complications associated with neutropenia.
Acknowledgments
We thank Eric Dougherty, PharmD, for assistance in producing granulocyte colony-stimulating factor data.
